% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Qaim:858324,
      author       = {Qaim, Syed M. and Scholten, Bernhard and Neumaier, Bernd},
      title        = {{N}ew developments in the production of theranostic pairs
                      of radionuclides},
      journal      = {Journal of radioanalytical and nuclear chemistry},
      volume       = {318},
      number       = {3},
      issn         = {1588-2780},
      address      = {Dordrecht [u.a.]},
      publisher    = {Springer Science + Business Media B.V},
      reportid     = {FZJ-2018-07212},
      pages        = {1493 - 1509},
      year         = {2018},
      abstract     = {A brief historical background of the development of the
                      theranostic approach in nuclear medicine is given and seven
                      theranostic pairs of radionuclides, namely 44gSc/47Sc,
                      64Cu/67Cu, 83Sr/89Sr, 86Y/90Y, 124I/131I, 152Tb/161Tb and
                      152Tb/149Tb, are considered. The first six pairs consist of
                      a positron and a β−-emitter whereas the seventh pair
                      consists of a positron and an α-particle emitter. The decay
                      properties of all those radionuclides are briefly mentioned
                      and their production methodologies are discussed. The
                      positron emitters 64Cu, 86Y and 124I are commonly produced
                      in sufficient quantities via the (p,n) reaction on the
                      respective highly enriched target isotope. A clinical scale
                      production of the positron emitter 44gSc has been achieved
                      via the generator route as well as via the (p,n) reaction,
                      but further development work is necessary. The positron
                      emitters 83Sr and 152Tb are under development. Among the
                      therapeutic radionuclides, 89Sr, 90Y and 131I are
                      commercially available and 161Tb can also be produced in
                      sufficient quantity at a nuclear reactor. Great efforts are
                      presently underway to produce 47Sc and 67Cu via neutron,
                      photon and charged particle induced reactions. The
                      radionuclide 149Tb is unique because it is an α-particle
                      emitter. The present method of production of 152Tb and 149Tb
                      involves the use of the spallation process in combination
                      with an on-line mass separator. The role of some emerging
                      irradiation facilities in the production of special
                      radionuclides is discussed.},
      cin          = {INM-5},
      ddc          = {540},
      cid          = {I:(DE-Juel1)INM-5-20090406},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000451746300005},
      doi          = {10.1007/s10967-018-6238-x},
      url          = {https://juser.fz-juelich.de/record/858324},
}